The prospect of yet does not pay off

Lately, pharmaceutical companies are actively engaged in the methodology development of CAR-T, which consists in the modification of T-cells taken from the patient, who after their re-introduction into the organism begins to destroy cancer cells.

From a scientific point of view, the results of this therapy are very good, especially if we are talking about rare and emerging cancers. However, financial success will have to wait more than a year, and this circumstance was the cause of a fair amount of skepticism from investors.

For example, reducing the profit of the company Gilead Sciences in the fourth quarter led to the recent depreciation of its stock. This was partly due to the fact that after the acquisition in 2017, $11 billion company Kite Pharma, specializing in the development of CAR-T, her needs had to allocate another 820 million At the same time, income from the sale Yescarta for which I bought Kite Pharma, amounted to only $271 million.

In addition, only $76 million in 2018 Novartis earned through sales similar drugs — Kymriah. A firm Juno Therapeutics, which in January 2018 Celgene paid $9 billion, and is still not released a single vehicle.

The reason for these disappointing results may be that the cost of such drugs is at least $373 thousand for the course and that they have dangerous side effects, due to which they are applied in a small number of hospitals.

Besides, it would take the conduct of clinical trials for many years to perfect this therapy.

However, pharmaceutical industry representatives are confident in the growth in demand for these medications, and, according to experts, the volume of sales Yescarta and Kymriah in 2023 will increase, respectively, to 1.6 billion and $851 million, which will provide Gilead and Novartis earnings growth of 43% and 61%.
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button